Addex Therapeutics Ltd - ADR Stock

$9.41

4.54% yesterday

Nasdaq, Jun 30, 10:00 pm CET

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Addex Therapeutics Ltd - ADR Stock price

$9.41

-164.94 94.60% 5Y

Nasdaq, Closing price Mon, Jun 30 2025

+0.41 4.54%

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$13.7m

Enterprise Value

$10.2m

Net debt

positive

Cash

$3.6m

Shares outstanding

98.4m

Valuation (TTM | estimate)

P/E

81.83 | negative

P/S

17.08 | 14.27

EV/Sales

12.72 | 10.63

EV/FCF

negative

P/B

85.24

Financial Health

Equity Ratio

90.63%

Return on Equity

72.91%

ROCE

-25.82%

ROIC

-34.70%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$810.0k | $958.0k

EBITDA

$-2.5m | $-4.3m

EBIT

$-2.7m

Net Income

$11.4m | $-7.5m

Free Cash Flow

$-4.4m

Growth (TTM | estimate)

Revenue

-53.45% | 87.84%

EBITDA

76.72% | -23.28%

EBIT

74.89%

Net Income

180.66% | -185.29%

Free Cash Flow

57.31%

Margin (TTM | estimate)

Gross

EBITDA

-308.77% | -444.00%

EBIT

-338.63%

Net

1,410.50% | -786.80%

Free Cash Flow

-540.15%

EPS

$0.11

FCF per Share

$-0.04

Short interest

0.25%

Employees

23.00

Rev per Employee

$20.00k

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Get Started for Free Today

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

2x Hold

20%

8x Sell

80%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Hold

20%

Sell

80%

Analyst Estimates with Stock Price Targets

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.81 0.81	53% 53% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	2.48 2.48	56% 56% 306%
- Research and Development Expense	0.87 0.87	90% 90% 107%
EBITDA	-2.50 -2.50	77% 77% -309%
- Depreciation and Amortization	0.24 0.24	26% 26% 30%
EBIT (Operating Income) EBIT	-2.74 -2.74	75% 75% -339%
Net Profit	11 11	181% 181% 1,411%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Addex Therapeutics Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

about 21 hours ago

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing...

Neutral

GlobeNewsWire

●

about 21 hours ago

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurode...

Neutral

GlobeNewsWire

●

6 days ago

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM).

More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office	Switzerland
CEO	Tim Dyer
Employees	23
Founded	2002
Website	www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now